HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (20) Citing Articles via Google Scholar Google Scholar Articles by Morrow, D. A. Articles by Antman, E. M. Search for Related Content PubMed PubMed Citation Articles by Morrow, D. A. Articles by Antman, E. M. Related Collections Proteomics and Protein Markers

The Search for a Biomarker of Cardiac Ischemia

¹ Cardiovascular Division, Department of Medicine, Brigham & Women’s Hospital, Boston, MA 02115

² Donald W. Reynolds, Cardiovascular Clinical Research Center, UT Southwestern Medical School, Dallas, TX 75390

^aAddress correspondence to this author at: Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St., Boston, MA 02115. Fax 617-734-7139; e-mail dmorrow@partners.org.

The first 300 words of the full text of this article appear below.

With 8 million patients arriving with nontraumatic chest pain to emergency departments in the US each year, the clinical evaluation, triage, and management of patients with possible acute coronary syndromes (ACS) presents a substantial medical and fiscal challenge (1). Although 2–5% of patients with myocardial infarction (MI) are inadvertently discharged from the emergency department and are a leading reason for malpractice claims, more than 50% of patients hospitalized for evaluation of chest pain are discharged with diagnoses other than ACS (1). Among those patients with definite ACS, early treatment may reduce the extent of myocardial injury, and thus rapid diagnosis and initiation of therapy is a central tenet of management (2). In addition, given the increasing array of treatments for the heterogeneous population of patients admitted with definite ACS, effective risk stratification and targeting of therapy have become a focus of contemporary management of ACS (2)(3). As such, the objectives of the initial assessment are twofold: (a) to assess the probability that the patient’s symptoms are related to acute coronary ischemia; and (b) to assess the patient’s risk of recurrent cardiac events, including death and recurrent ischemia (2). In the ideal circumstance, physicians could reliably identify patients with definite ACS and begin appropriate therapy as early as possible, as well as distinguish those without acute coronary ischemia who may be candidates for early discharge without extended observation in the emergency department, chest pain unit, or inpatient wards.

Unfortunately, other than in the 15% of patients with ACS who present with diagnostic ST-segment elevation, our basic clinical tools (history, physical exam, and electrocardiogram) for making the diagnosis of ACS offer limited sensitivity and specificity. Biomarkers of myocardial necrosis add importantly to these other clinical tools and are a critical . . . [Full Text of this Article]

attributes of an ideal biomarker for myocardial ischemia

research challenges

albumin cobalt binding as a test for myocardial ischemia

The following articles in journals at HighWire Press have cited this article:

				N. Morikawa, Y. Kawai, K. Arakawa, T. Kumamoto, I. Miyamori, H. Akao, M. Kitayama, K. Kajinami, J.-D. Lee, H. Takeshita, et al. Serum deoxyribonuclease I activity can be used as a novel marker of transient myocardial ischaemia: results in vasospastic angina pectoris induced by provocation test Eur. Heart J., December 2, 2007; 28(24): 2992 - 2997. [Abstract] [Full Text] [PDF]

				NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, and R. H. Christenson National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Circulation, April 3, 2007; 115(13): e356 - e375. [Full Text] [PDF]

				NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Clin. Chem., April 1, 2007; 53(4): 552 - 574. [Full Text] [PDF]

				R. S. Vasan Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations Circulation, May 16, 2006; 113(19): 2335 - 2362. [Full Text] [PDF]

				D Roy, J Quiles, D C Gaze, P Collinson, J C Kaski, and G F Baxter Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin Heart, January 1, 2006; 92(1): 113 - 114. [Full Text] [PDF]

				M. S. Sabatine, E. Liu, D. A. Morrow, E. Heller, R. McCarroll, R. Wiegand, G. F. Berriz, F. P. Roth, and R. E. Gerszten Metabolomic Identification of Novel Biomarkers of Myocardial Ischemia Circulation, December 20, 2005; 112(25): 3868 - 3875. [Abstract] [Full Text] [PDF]

				M. S. Sabatine When prognosis precedes diagnosis: putting the cart before the horse Can. Med. Assoc. J., June 21, 2005; 172(13): 1697 - 1698. [Full Text] [PDF]

				M. Panteghini Role and importance of biochemical markers in clinical cardiology Eur. Heart J., July 2, 2004; 25(14): 1187 - 1196. [Abstract] [Full Text] [PDF]